AMBS .062 News out earlier today 1.7 million volum
Post# of 306
AMBS .062 News out earlier today 1.7 million volume
http://www.amarantus.com/about-us/company-overview
Company Overview
Amarantus BioScience Holdings, Inc. is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.
Neurodegenerative diseases such as Parkinson’s, ALS and Alzheimer’s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s Disease and other human diseases.
(0)
(0)